Thiotepa

Product manufactured by Sagent Pharmaceuticals

Application Nr Approved Date Route Status External Links
ANDA209150 None Intracavitary None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Thiotepa For Injection Has Been Tried With Varying Results In The Palliation Of A Wide Variety Of Neoplastic Diseases. However, The Most Consistent Results Have Been Seen In The Following Tumors: Adenocarcinoma Of The Breast. Adenocarcinoma Of The Ovary. For Controlling Intracavitary Effusions Secondary To Diffuse Or Localized Neoplastic Diseases Of Various Serosal Cavities. For The Treatment Of Superficial Papillary Carcinoma Of The Urinary Bladder. While Now Largely Superseded By Other Treatments, Thiotepa For Injection Has Been Effective Against Other Lymphomas, Such As Lymphosarcoma And Hodgkin's Disease.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Thiotepa THIOTEPA ZINC1530867

Comments